SERNOVA Forum: Community User: COLOGNE79

...ist auf LinkedIn top aktuell 😂🙈

Ist doch ein altes Interview - oder?

Das ist alles steinalt diese News!!! Fällt auch kaum jemand noch drauf rein…..

Das ist fast ein Jahr alt

Successful Results Using Sernova’s Cell Pouch SystemTM with Evotec’s iPSC-Derived Islet-like Clusters for Type 1 Diabetes Presented at the 4th IPITA / HSCI / JDRF Summit • Evotec’s **** GMP manufacturing process has been designed to produce induced pluripotent stem cell (iPSC)-derived islet-like clusters (ILCs) with high insulin-producing beta cell content as well as glucagon and somatostatin (produced by alpha cells and delta cells, respectively), similar to human islets • The ILCs are cryopreserved during manufacturing, enabling storage of mass volumes and cost efficient on-demand worldwide delivery as required • Results from a type 1 diabetes (T1D) preclinical model with Evotec’s ILCs implanted into Sernova’s Cell PouchTM demonstrated robust and durable insulin independence with blood C- peptide levels and glucose tolerance test results equivalent to a test group with human islets • An additional T1D study with Evotec’s ILCs demonstrated sustained normalization of blood sugar levels in diabetic mice throughout the 320 day term of the study • IND filing and Phase 1/2 clinical program with Sernova’s Cell Pouch and Evotec’s iPSC ILCs on track for 2024

Das stimmt. Leider fallen auf Karsten noch viele rein. Wird aber schon weniger. Gruppen sind auch schon anonym 😀

schon wieder alte News,nur etwas aufgefrischt.Peinlich mal gucken wann die 50 Cent fallen. Dieses Jahr ist es soweit

Manufacturing of optimized human islet-like clusters (ILCs) from iPSCs and functional testing of an ILC **** Cell PouchTM combination in vivo Audrey Holtzinger1, Simone Strauch1, Thomas Reinbothe1, Claudia Wrzos1, Andreas Scheel1, Cord Dohrmann1, Arash Memarnejadian2, Pardis Pakshir2, Philip M. Toleikis2, Matthias Austen1. 1Evotec International GmbH, Goettingen, Germany; 2Sernova Corp., London, ON, Canada We have developed a scalable and comprehensive process for GMP manufacturing of ILCs from a human GMP-grade iPSC line for cell therapy in human insulin-dependent diabetes. The product candidate is characterized by a high beta cell and endocrine cell fraction and has been optimized for low-to-absent unwanted cell content. Functional studies in diabetic rodents show robust normalization of key diabetes disease parameters upon implantation of ILCs under the kidney capsule or in Theracyte encapsulation devices, such as glucose tolerance, random fed glucose levels and circulating human C-peptide. Long-term studies demonstrate no loss of function over extended periods of time, with glucose-lowering activity on a per-beta-cell basis within the same range as observed with human donor islets. Recently, Evotec entered a collaboration with Sernova Corp., which has developed the proprietary Cell PouchTM device. Following implantation, the Cell PouchTM develops a vascularized environment to support engraftment and function of therapeutic cells. The device is currently in clinical trials with human donor islets (ClinicalTrials.gov Identifier: NCT03513939). When tested in combination with the Sernova Cell PouchTM pre-implanted in diabetic NSG mice, our ILCs showed excellent function, indicating that the Cell PouchTM provides a beneficial environment not only for human donor islets but also for iPSC-derived ILCs. iPSC-derived ILC manufacturing scale-up and tech transfer activities to Evotec’s GMP cell manufacturing team are well underway in preparation for human clinical trial evaluation.

https://cm.betacells.org/mobis/lecture/45 https://theracyte.com/the-theracyte-system/

In Kombination mit dem Sernova Cell Pouch TM, der diabetischen NSG-Mäusen vorimplantiert wurde, zeigten unsere ILCs eine exzellente Funktion, was darauf hindeutet, dass der Cell Pouch TM nicht nur für menschliche Spenderinseln, sondern auch für die Herstellung von iPCS-abgeleiteten ILCs geeignet ist und dass Evotecs GMP-Zellherstellungsteam in Vorbereitung auf die Evaluierung klinischer Studien am Menschen in vollem Gange ist.....

https://twitter.com/SernovaCorp/status/1650484956055982081

Presenter Matthias Austen, Germany SVP Cell Therapy Cell Therapy Evotec International GmbH Abstract Manufacturing of optimized human islet-like clusters (ILCs) from iPSCs and functional testing of an ILC + Cell PouchTM combination in vivo https://cm.betacells.org/mobis/lecture/45

Also hier ist ja echt Hopfen und Malz verloren 😭

Der Typ ist ein absoluter vollamateur 🙈

×× merkwürdige Sternchen. Empfehlungen empfehlen empfehlenswert ... nur ein Test 🤷‍♂️